Adirondack Research & Management’s Pfizer PFE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2021
Q3 | $349K | Sell |
8,115
-650
| -7% | -$28.8K | 0.42% | 81 |
|
|
2021
Q2 | $343K | Sell |
8,765
-260
| -3% | -$10.1K | 0.4% | 80 |
|
|
2021
Q1 | $327K | Buy |
9,025
+50
| +0.6% | +$1.77K | 0.39% | 77 |
|
|
2020
Q4 | $330K | Sell |
8,975
-485
| -5% | -$17.8K | 0.45% | 66 |
|
|
2020
Q3 | $329K | Hold |
9,460
| – | – | 0.46% | 60 |
|
|
2020
Q2 | $293K | Sell |
9,460
-10
| -0.1% | -$340 | 0.38% | 63 |
|
|
2020
Q1 | $293K | Hold |
9,470
| – | – | 0.41% | 59 |
|
|
2019
Q4 | $352K | Hold |
9,470
| – | – | 0.31% | 71 |
|
|
2019
Q3 | $323K | Hold |
9,470
| – | – | 0.28% | 79 |
|
|
2019
Q2 | $389K | Hold |
9,470
| – | – | 0.28% | 74 |
|
|
2019
Q1 | $382K | Hold |
9,470
| – | – | 0.24% | 81 |
|
|
2018
Q4 | $392K | Hold |
9,470
| – | – | 0.25% | 77 |
|
|
2018
Q3 | $396K | Hold |
9,470
| – | – | 0.15% | 98 |
|
|
2018
Q2 | $347K | Hold |
9,470
| – | – | 0.14% | 97 |
|
|
2018
Q1 | $319K | Sell |
9,470
-2,741
| -22% | -$94.2K | 0.13% | 102 |
|
|
2017
Q4 | $420K | Hold |
12,211
| – | – | 0.16% | 92 |
|
|
2017
Q3 | $414K | Hold |
12,211
| – | – | 0.16% | 90 |
|
|
2017
Q2 | $389K | Hold |
12,211
| – | – | 0.15% | 93 |
|
|
2017
Q1 | $396K | Buy |
12,211
+327
| +3% | +$10.3K | 0.14% | 98 |
|
|
2016
Q4 | $366K | Hold |
11,884
| – | – | 0.12% | 94 |
|
|
2016
Q3 | $382K | Hold |
11,884
| – | – | 0.14% | 95 |
|
|
2016
Q2 | $397K | Hold |
11,884
| – | – | 0.15% | 91 |
|
|
2016
Q1 | $334K | Buy |
11,884
+896
| +8% | +$25.6K | 0.12% | 94 |
|
|
2015
Q4 | $337K | Hold |
10,988
| – | – | 0.12% | 88 |
|
|
2015
Q3 | $327K | Hold |
10,988
| – | – | 0.13% | 94 |
|
|
2015
Q2 | $350K | Hold |
10,988
| – | – | 0.13% | 91 |
|
|
2015
Q1 | $363K | Sell |
10,988
-506
| -4% | -$16.1K | 0.14% | 86 |
|
|
2014
Q4 | $340K | Hold |
11,494
| – | – | 0.13% | 94 |
|
|
2014
Q3 | $322K | Sell |
11,494
-105
| -0.9% | -$2.95K | 0.12% | 91 |
|
|
2014
Q2 | $327K | Sell |
11,599
-185
| -2% | -$5.27K | 0.11% | 94 |
|
|
2014
Q1 | $359K | Hold |
11,784
| – | – | 0.14% | 92 |
|
|
2013
Q4 | $342K | Sell |
11,784
-52
| -0.4% | -$1.51K | 0.17% | 90 |
|
|
2013
Q3 | $323K | Hold |
11,836
| – | – | 0.19% | 88 |
|
|
2013
Q2 | $315K | Buy |
+11,836
| New | +$327K | 0.24% | 86 |
|
Other funds holding PFE
Adirondack Research & Management's PFE Position: Q3 2021 in Review
Adirondack Research & Management reduced its Pfizer (PFE) stake by 7.4% in Q3 2021, selling an estimated $28.8K and leaving 8,115 shares worth $349K. The position accounts for 0.42% of the portfolio, ranked #81.
Adirondack Research & Management first reported a position in PFE in Q2 2013 and has held it in 34 quarters since. The position peaked at $420K in Q4 2017. 2,806 funds tracked by Wall St. Rank hold PFE as of Q3 2021.
- Adirondack Research & Management held 8,115 shares of Pfizer worth $349K as of Q3 2021.
- Adirondack Research & Management sold 650 Pfizer shares in Q3 2021, an estimated $28.8K.
- Pfizer made up 0.42% of Adirondack Research & Management's portfolio in Q3 2021, its #81 holding.
- Adirondack Research & Management first reported a position in Pfizer in Q2 2013 and has held it in 34 quarters since.
- Adirondack Research & Management's Pfizer position peaked at $420K in Q4 2017.
- 2,806 funds tracked by Wall St. Rank held Pfizer as of Q3 2021.
Based on Adirondack Research & Management's 13F filing for Q3 2021, filed 29 Oct 2021.